Monogram Orthopaedics (NASDAQ:MGRM) Given New $5.40 Price Target at Roth Mkm

Monogram Orthopaedics (NASDAQ:MGRMFree Report) had its price objective raised by Roth Mkm from $4.00 to $5.40 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Roth Capital upgraded Monogram Orthopaedics to a “strong-buy” rating in a report on Monday, December 9th.

Read Our Latest Research Report on Monogram Orthopaedics

Monogram Orthopaedics Price Performance

Shares of MGRM opened at $3.43 on Tuesday. The stock has a market capitalization of $121.04 million, a price-to-earnings ratio of -7.30 and a beta of 1.66. The business’s 50 day simple moving average is $2.58 and its 200-day simple moving average is $2.50. Monogram Orthopaedics has a 1 year low of $1.53 and a 1 year high of $4.90.

Monogram Orthopaedics (NASDAQ:MGRMGet Free Report) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, sell-side analysts expect that Monogram Orthopaedics will post -0.49 earnings per share for the current year.

Institutional Trading of Monogram Orthopaedics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Monogram Orthopaedics in the fourth quarter worth $25,000. Barclays PLC purchased a new stake in Monogram Orthopaedics in the third quarter worth $29,000. Wells Fargo & Company MN increased its stake in Monogram Orthopaedics by 286.6% in the fourth quarter. Wells Fargo & Company MN now owns 11,597 shares of the company’s stock worth $27,000 after purchasing an additional 8,597 shares during the period. Orion Portfolio Solutions LLC purchased a new stake in Monogram Orthopaedics in the fourth quarter worth $31,000. Finally, State Street Corp purchased a new stake in Monogram Orthopaedics in the third quarter worth $62,000. Hedge funds and other institutional investors own 0.45% of the company’s stock.

Monogram Orthopaedics Company Profile

(Get Free Report)

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.

Further Reading

Receive News & Ratings for Monogram Orthopaedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monogram Orthopaedics and related companies with MarketBeat.com's FREE daily email newsletter.